摘要
目的浅析硝普钠联合多巴胺治疗心力衰竭的临床疗效以及安全性。方法 80例心力衰竭患者,按照患者入院治疗顺序分为参考组和研究组,每组40例。参考组在常规治疗基础上加入多巴胺治疗,研究组在参考组基础上加入硝普钠治疗。比较两组临床疗效、治疗前后心功能指标及生化指标、不良反应发生情况。结果研究组治疗总有效率95.0%高于参考组的80.0%,差异具有统计学意义(P<0.05)。治疗后,研究组左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室短轴缩短率(LVFS)水平分别为(43.6±0.5)%、(60.0±0.5)mm、(37.8±0.3)%,均优于参考组的(39.1±0.1)%、(65.2±0.6)mm、(32.6±0.3)%,差异均具有统计学意义(P<0.05);研究组超敏C反应蛋白(hs-CRP)、脑利钠肽(BNP)水平分别为(2.1±0.3)mg/L、(219.5±56.3)pg/ml,均优于参考组的(3.9±0.3)mg/L、(299.6±51.2)pg/ml,差异均具有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论心力衰竭临床治疗方案中采取硝普钠联合多巴胺治疗效果明显,安全性高,具有推荐使用价值,帮助患者尽快获得健康。
Objective To analyze the clinical efficacy and safety of sodium nitroprusside combined with dopamine in the treatment of heart failure. Methods A total of 80 patients with heart failure were divided into control group and research group by admission order, with 40 cases in each group. The control group was treated by dopamine on the basis of conventional therapy, and the research group was treated by sodium nitroprusside on the basis of the control group. The clinical efficacy, cardiac function and biochemical indexes before and after treatment, and occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment of the research group was 95.0%, which was higher than that of the control group 80.0%, and the difference was statistically significant(P<0.05). After treatment, the levels of left ventricular ejection fraction(LVEF), left ventricular end-diastolic diameter(LVEDD), and left ventricular fractional shortening(LVFS) of the research group were(43.6±0.5)%,(60.0± 0.5) mm and(37.8±0.3)%, which were all better than those of the control group(39.1±0.1)%,(65.2±0.6) mm and(32.6±0.3)%, and the difference was statistically significant(P<0.05). The levels of high sensitive C-reactive protein(hs-CRP) and brain natriuretic peptide(BNP) of the research group were(2.1±0.3) mg/L and(219.5± 56.3) pg/ml respectively, which were all better than those of the control group(3.9±0.3) mg/L and(299.6± 51.2) pg/ml, and the difference was statistically significant(P<0.05). There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05). Conclusion Combination of sodium nitroprusside and dopamine shows obvious therapeutic effect for clinical treatment of heart failure with high safety, and has recommended value to help patients get heath as soon as possible.
作者
陈柏桦
CHEN Bai-hua(General Department,Guangzhou Zengcheng District Xintang Hospital,Guangzhou 511340,China)
出处
《中国实用医药》
2020年第10期1-3,共3页
China Practical Medicine
关键词
心力衰竭
硝普钠
多巴胺
心功能
临床疗效
Heart failure
Sodium nitroprusside
Dopamine
Cardiac function
Clinical efficacy
